BETSHY

Category: Science

  • Trigeminal Neuralgia in the Long-Term: Bidirectional Impact on Psychological Health

    Trigeminal Neuralgia in the Long-Term: Bidirectional Impact on Psychological Health

    Trigeminal Neuralgia (TN) is a rare but devastating neuropathic condition characterised by sudden, electric shock-like episodes of excruciating facial pain distributed along the branches of the trigeminal nerve — the fifth cranial nerve, responsible for sensation across the face. The attacks are frequently triggered by the most mundane of stimuli: brushing teeth, speaking, eating, or even the touch of a gentle breeze. The severity of pain has long been described as among the most intense that human physiology is capable of producing, earning TN its well-known and historically significant designation as the “suicide disease” (Neto et al., 2025 ).

    While this label has been challenged in recent years as medical and surgical treatments have advanced, its existence is not without clinical basis. The psychological burden imposed by long-term TN is substantial, multidimensional, and — critically — profoundly underestimated within mainstream healthcare. This article examines how trigeminal neuralgia influences psychological changes over time, exploring the bidirectional relationship between chronic pain and mental health, the specific psychiatric conditions associated with TN, the risk of suicidality, the disruption to social and occupational functioning, and what the evidence recommends for integrated clinical management.

    Advertisements

    A Bidirectional Relationship: Pain and Mental Health

    The relationship between trigeminal neuralgia and psychological disorders is not unidirectional. Traditionally, the assumption has been that the pain of TN causes secondary mood changes such as depression and anxiety — a logical and intuitive proposition. However, emerging research using Mendelian randomisation analysis — a methodology that applies genetic markers to establish causal direction — has demonstrated that the relationship is in fact bidirectional: not only does TN precipitate psychiatric illness, but pre-existing mental health conditions including depression, anxiety, and insomnia also significantly increase the risk of developing TN in the first instance (Wang et al., 2025).

    A landmark 2025 study published in The Journal of Headache and Pain found that people with depression were more than twice as likely to develop TN, while insomnia and anxiety also significantly elevated TN onset risk. Conversely, carrying a diagnosis of TN increased the risk of developing anxiety by 43%, depression by 30%, and insomnia by nearly 40% (TNA, 2025). Furthermore, the study confirmed that longer disease duration and broader trigeminal nerve involvement were independently associated with increased severity of depressive, anxiety, and insomnia symptoms — underscoring a dose-response relationship between the chronicity of TN and the depth of its psychological toll (Wang et al., 2025).

    Depression: The Most Prevalent Psychological Consequence

    Depression is the most consistently documented psychological comorbidity in TN populations and one of the most clinically consequential. The mechanism is well-evidenced: chronic, unrelenting pain of the intensity characteristic of TN depletes neurochemical resources, disrupts sleep architecture, undermines the capacity for daily functioning, and progressively narrows the individual’s world — all known aetiological contributors to major depressive disorder (Wu et al., 2019). The unpredictability of TN attacks — which can occur without warning at any moment during waking hours — generates a state of sustained psychological vigilance that, over time, mirrors the cognitive and physiological features of a depressive episode.

    A systematic review published in Neurosurgery Reviews in 2025 — the first of its kind to comprehensively examine the psychological burden of TN — confirmed that TN patients carry significantly elevated rates of depressive disorders across multiple validated assessment tools, including the PHQ-9, Hamilton Depression Rating Scale, and Hospital Anxiety and Depression Scale. Critically, the review also found that surgical treatments, particularly microvascular decompression (MVD), effectively alleviated both pain and depressive symptoms, while multidisciplinary approaches combining psychological support with neurorehabilitation yielded the best overall outcomes — a finding with direct implications for how NHS services structure TN care pathways (Martinelli et al., 2025).

    Anxiety, Anticipatory Fear, and Catastrophising

    Anxiety in TN takes a form that is, in many respects, distinct from generalised anxiety disorder as it presents in the broader population. The central driver is anticipatory fear — the perpetual, hypervigilant dread of the next attack. Because TN pain is triggered by ordinary activities that cannot be permanently avoided — talking, eating, drinking, facial exposure to air — affected individuals frequently develop avoidance behaviours that progressively restrict their lives. They stop eating in public. They cease speaking unnecessarily. They avoid wind, cold, and touch with an intensity that begins to resemble phobic avoidance (Wu et al., 2019).

    Research comparing patients with TN against those with persistent idiopathic facial pain found that anxiety symptoms were significantly more elevated in the TN group, and that for individuals reporting prior trauma exposure, PTSD symptoms were also significantly greater among TN patients than comparison groups (ScienceDirect, 2025). The phenomenon of pain catastrophising — a cognitive pattern in which individuals magnify the threat value of pain, ruminate on its impact, and feel helpless in the face of it — is documented at elevated rates in TN and has been shown to independently worsen both pain perception and psychological outcomes over time (Frontiers in Neurology, 2025).

    PTSD, Trauma, and the Neurological Siege

    The conceptualisation of TN-related suffering within a trauma framework is gaining increasing traction in the clinical literature, and it is not difficult to understand why. The lived experience of TN — sudden, violent, entirely unpredictable episodes of pain that resist personal control and occur in the context of innocuous daily activities — shares structural features with the traumatic experiences that give rise to post-traumatic stress disorder. The nervous system learns to associate ordinary environmental stimuli with overwhelming threat, generating the hyperarousal, intrusive re-experiencing, and avoidance behaviours that characterise PTSD (Neto et al., 2025 ).

    Emerging evidence confirms that PTSD symptoms are measurably elevated in TN populations, particularly in those with longer disease duration, greater pain intensity, and inadequate treatment response. The systematic review by Martinelli et al. noted that sleep disorders — which are independently associated with the development and maintenance of PTSD — were among the most prevalent and underaddressed comorbidities in TN patients, creating a reinforcing cycle of neurological and psychological distress that becomes progressively more difficult to interrupt without targeted intervention (Martinelli et al., 2025).

    Suicidality: An Urgent and Under-Addressed Clinical Concern

    The designation of TN as the “suicide disease” demands honest and careful clinical scrutiny. A 2025 study conducted by researchers from Harvard Medical School and Massachusetts General Hospital — the largest study to date examining suicidality in TN — recruited 229 adults with TN and related conditions between December 2023 and January 2024. Their findings were sobering: suicidal ideation was found at clinically significant rates within the sample, and was strongly associated with high pain intensity, elevated anxiety, and severe depression (Fishbein, Bakhshaie and Greenberg, 2025). The authors concluded that suicidality is an urgent yet substantially under-addressed concern among adults with TN, and that its association with pain intensity places comprehensive psychological screening at the centre of responsible clinical management.

    Research examining psychological status in TN patients before and after surgical intervention has further identified that the risk of suicidal ideation is significantly higher in patients with atypical TN (TN2) than in those with classical TN (TN1), requiring more intensive psychological monitoring in this subgroup — and supporting the argument that indications for surgical treatment should be established with urgency in patients at elevated psychological risk (ScienceDirect, 2021). While the “suicide disease” label may now be contextually outdated given advances in surgical and pharmacological treatment, it retains clinical utility as a reminder of the severity of psychological risk that chronic, inadequately managed TN produces (Neto et al., 2025 ).

    Social Isolation, Identity, and Occupational Disruption

    Beyond the domain of discrete psychiatric diagnoses, TN exerts a pervasive and devastating influence on social functioning, personal identity, and occupational engagement. The avoidance behaviours generated by anticipatory fear — the withdrawal from eating, speaking, and social interaction — progressively erode the structures around which personal identity is built. Work becomes impossible, or severely constrained, for many individuals during active disease phases. Social relationships deteriorate under the weight of unexplained withdrawal and communicative limitation. For those who depend on speech professionally — teachers, therapists, lawyers, performers — the occupational consequences can be total and permanent (TNA, 2025).

    The psychological literature consistently identifies social isolation as both a consequence and an amplifier of chronic pain, generating a self-reinforcing cycle in which pain produces withdrawal, withdrawal reduces protective social buffering, and the absence of social support intensifies the subjective experience and psychological weight of pain. In TN, where the very act of social communication — speaking — can trigger an attack, this cycle is particularly vicious and particularly difficult to interrupt without targeted psychosocial intervention alongside physical pain management (Frontiers in Neurology, 2025).

    Treatment Implications: The Case for Multidisciplinary Care

    The weight of evidence reviewed here makes a compelling and unambiguous case for the integration of psychological support into the standard clinical management of trigeminal neuralgia. Pharmacological and surgical interventions — carbamazepine and oxcarbazepine as first-line medications, microvascular decompression as the preferred surgical option for suitable candidates — address the neurological substrate of TN pain with variable success, but do not in themselves address the psychological sequelae that accumulate across the duration of the illness (Martinelli et al., 2025).

    The systematic review by Martinelli et al. explicitly concluded that standardising psychological assessment and treatment methodologies is crucial for optimising TN management outcomes — and that multidisciplinary approaches combining psychological support with neurorehabilitation consistently yield superior results to purely biomedical approaches alone. The Trigeminal Neuralgia Association UK has similarly called for psychological therapy, pain counselling, and sleep support to be embedded as standard within TN care pathways — not optional additions, but structural components of responsible clinical provision (TNA, 2025).

    Conclusion

    Trigeminal neuralgia is not merely a condition of the face. It is a condition of the whole person — neurological in origin, but psychological in consequence, social in impact, and existential in the challenges it poses to identity, connection, and the basic quality of human experience. The long-term psychological changes it produces — depression, anxiety, anticipatory fear, PTSD-like trauma responses, suicidal ideation, social withdrawal, and occupational collapse — are not incidental features of living with chronic pain. They are clinical realities that demand clinical responses: structured, evidence-based, and delivered alongside rather than after physical pain management. Recognising TN as the biopsychosocial emergency it truly is remains one of the most important steps the clinical and research communities can take toward meaningfully improving outcomes for those who live with this condition.

    If you or someone you know is living with chronic pain and experiencing thoughts of suicide or self-harm, please contact the Samaritans on 116 123 (free, 24/7 in the UK) or speak to your GP or local NHS mental health service as soon as possible. If you are seeking help from outside the UK, call your local support service.

    References

    Fishbein, N.S., Bakhshaie, J. and Greenberg, J. (2025) ‘Suicidal Ideation and Self-Injury in Trigeminal Neuralgia’, Journal of Pain Research, 18, pp. 2003–2010. Available at: https://www.dovepress.com/suicidal-ideation-and-self-injury-in-trigeminal-neuralgia-peer-reviewed-fulltext-article-JPR (Accessed: 10 June 2026).

    Frontiers in Neurology (2025) ‘Effects of risk factor-based targeted nursing intervention on psychological status, sleep quality, and pain in patients with trigeminal neuralgia’, Frontiers in Neurology. Available at: https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1681364/full (Accessed: 10 June 2026).

    Martinelli, R., Vannuccini, S., Burattini, B., D’Alessandris, Q.G., D’Ercole, M., Izzo, A., Chieffo, D.P.R., Doglietto, F. and Montano, N. (2025) ‘Psychological assessment in patients affected by trigeminal neuralgia: a systematic review’, Neurosurgery Reviews, 48(1), 414. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069416/ (Accessed: 10 June 2026).

    Neto, R., Fonseca Silva, B., Remelhe, M. and Araujo, R. (2025) ‘Trigeminal Neuralgia — rethinking the “suicide disease” label’, European Psychiatry. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12438733/ (Accessed: 10 June 2026).

    ScienceDirect (2021) ‘Psychological status before and after surgery in patients with trigeminal neuralgia’, Journal of Clinical Neuroscience. Available at: https://www.sciencedirect.com/science/article/abs/pii/S0303846721001050 (Accessed: 10 June 2026).

    ScienceDirect (2025) ‘Psychological profiles and sleep quality differences between patients with persistent idiopathic facial pain and trigeminal neuralgia: a 7-year retrospective study’, Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. Available at: https://www.sciencedirect.com/science/article/abs/pii/S2212440325007746 (Accessed: 10 June 2026).

    Trigeminal Neuralgia Association UK (2025) Trigeminal Neuralgia and Mental Health. Available at: https://www.tna.org.uk/ceo/trigeminal-neuralgia-and-mental-health/ (Accessed: 10 June 2026).

    Wang, J., Li, M., Zhang, Z., Duan, Y., Zhang, Z., Liu, H. et al. (2025) ‘Association between mental disorders and trigeminal neuralgia: a cohort study and Mendelian randomization analysis’, The Journal of Headache and Pain, 26, 74. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11992777/ (Accessed: 10 June 2026).

    Wu, T.H., Hu, L.Y., Lu, T. et al. (2019) ‘Effects of Depression and Anxiety on Microvascular Decompression Outcome for Trigeminal Neuralgia Patients’, World Neurosurgery. Available at: https://www.sciencedirect.com/science/article/abs/pii/S1878875019311891 (Accessed: 10 June 2026).

  • Borderline Personality Disorder and Life Expectancy: Examining the Evidence Behind the Premature Death Claim

    Borderline Personality Disorder and Life Expectancy: Examining the Evidence Behind the Premature Death Claim

    Among the many sobering realities associated with Borderline Personality Disorder (BPD), perhaps none demands more urgent clinical and public attention than its profound impact on life expectancy. A claim now circulating widely in mental health discourse — that BPD can shorten a person’s life by up to 20 years — is not a figure born of speculation. It is grounded in a growing body of peer-reviewed longitudinal research that collectively paints a troubling picture of premature mortality risk in this population. Yet the “20-year” headline, while broadly accurate, is more nuanced than it first appears. The evidence points to a range of outcomes shaped by comorbidities, socioeconomic factors, access to care, and biological mechanisms that science is only beginning to fully understand. This article examines that evidence in detail, interrogating where the figure comes from, what drives it, and what can be done to narrow the gap.

    Advertisements

    Where Does the “20-Year” Figure Come From?

    The most frequently cited estimate is that individuals with BPD face a reduction in life expectancy of approximately 10 to 20 years compared to the general population (Euler et al., 2025 ). Other studies extend this further: longitudinal research has estimated that people with personality disturbances more broadly — with BPD representing the most clinically severe — face a reduction in life expectancy of between 13 and 27.5 years, owing to a substantially elevated all-cause mortality risk, particularly among younger individuals (Rincón Ferrari et al., 2024). This wide range reflects genuine variation in study design, sample characteristics, and follow-up periods — but across all estimates, the direction of the evidence is unambiguous: BPD is associated with markedly shortened lifespans.

    The most methodologically rigorous evidence underpinning this claim comes from the McLean Study of Adult Development (MSAD), a prospective 24-year longitudinal investigation conducted at Harvard-affiliated McLean Hospital. Following 290 patients with BPD against 72 comparison patients with other personality disorders, the study found that after 24 years, 5.9% of BPD patients had died by suicide, compared with 1.4% of comparison patients. More strikingly, a further 14.0% of BPD patients died from other causes — nearly three times the 5.5% rate observed in the comparison group (Temes et al., 2019). The principal investigators concluded that premature mortality in BPD is comparable in scale to that observed in other serious mental illnesses, including schizophrenia and treatment-resistant mood disorders (Medscape, 2019).

    Suicide: Real, Significant, But Not the Whole Story

    Any honest discussion of BPD mortality must begin with suicide, which remains the most clinically visible and statistically documented contributor to early death in this population. Between 46% and 92% of individuals with BPD will attempt suicide at least once during their lifetime, and between 3% and 10% will die by suicide — a rate dramatically higher than both the general population and many other psychiatric diagnoses (Euler et al., 2025 ). Factors shown to predict completed suicide in BPD include prior suicidal behaviour, a greater number of psychiatric hospitalisations, and the presence of significant psychiatric comorbidities (Medscape, 2019).

    However, a critical finding from the McLean MSAD and subsequent studies is that suicide alone does not account for the full extent of the mortality gap. In the McLean cohort, non-suicidal causes of death — including cardiovascular disease (n=11), substance-related complications (n=5), cancer (n=4), and accidents (n=4) — collectively exceeded suicide as a cause of premature death in BPD patients who did not achieve recovery (Temes et al., 2019). This finding has significant implications for how clinicians approach the condition: a singular focus on suicide prevention, while essential, is insufficient to address the full spectrum of life-threatening risk.

    Physical Health: The Silent Driver of Early Death

    The physical health burden carried by individuals with BPD is substantially underappreciated in mainstream clinical and public discourse. Research confirms that BPD independently elevates the risk of cardiovascular disease, hypertension, obesity, diabetes, arteriosclerosis, arthritis, gastrointestinal disorders, hepatic disease, and sexually transmitted infections (Rincón Ferrari et al., 2024). A dedicated echocardiographic study found that female BPD patients showed significantly increased epicardial adipose tissue — an established sensitive marker for cardiovascular disease risk — alongside reduced indices of cardiac function, compared to matched controls, suggesting that structural cardiac changes may begin early in the illness course (Euler et al., 2025 ).

    The theoretical framework known as the “Pace-of-Life Syndrome” offers one explanatory model for why physical deterioration occurs so pervasively in BPD. Rooted in evolutionary biology, this framework argues that the chronic stress, early adversity, and emotional hyperreactivity characteristic of BPD produce a state of elevated allostatic load — the cumulative physiological wear caused by chronic psychological stress — that accelerates biological ageing and systemic organ damage over time (Otto, Kokkelink and Brüne, 2021). In clinical settings, BPD is associated with an 8.3-fold higher all-cause mortality compared to the general population — a figure that situates it firmly in the category of serious public health concern (Otto, Kokkelink and Brüne, 2021).

    Comorbidities and the Compounding Effect

    BPD rarely exists in isolation, and the life expectancy implications of its comorbidities are considerable. The vast majority of individuals diagnosed with BPD also experience at least one mood disorder — most commonly major depressive disorder or bipolar disorder — alongside elevated rates of anxiety disorders, post-traumatic stress disorder, eating disorders, and attention-deficit hyperactivity disorder (MH Stats, 2026). Substance Use Disorders (SUD) are present in approximately 60% of clinical BPD samples and constitute one of the strongest independent predictors of non-suicidal premature death, contributing directly to cardiovascular complications, accidental overdose, and immune system compromise over time (Grouport Therapy, 2023).

    The temporal dimension of BPD across the lifespan adds further complexity. Research shows that while core BPD symptoms — including affective dysregulation, impulsivity, and suicidality — tend to diminish in intensity with age, maladaptive interpersonal functioning and functional impairment often persist and evolve in presentation, meaning that risk does not simply disappear as patients grow older (Zanarini et al., 2019). The cumulative toll of decades of emotional dysregulation, poor health behaviours, medication side effects, and systemic neglect by healthcare services produces a form of accelerated biological ageing that is difficult to reverse in later life.

    Stigma, Systemic Barriers, and the Access Gap

    A crucial but frequently overlooked contributor to the mortality gap in BPD is the pervasive stigma attached to the diagnosis — both among the general public and within healthcare systems themselves. Individuals with BPD consistently report experiencing negative, dismissive, or even punitive treatment from health practitioners, which generates significant reluctance to seek medical care and sustain treatment engagement (Euler et al., 2025 ). This stigma compounds the already considerable barriers to accessing consistent, high-quality physical and mental healthcare — particularly in under-resourced healthcare systems where BPD-specific expertise is limited (MH Stats, 2026). A significant treatment delay exists between the onset of BPD symptoms, which often emerge in adolescence, and the point at which an individual first receives an accurate diagnosis and appropriate care (MH Stats, 2026).

    Closing the Gap: What the Evidence Recommends

    The mortality gap associated with BPD is not immutable. Effective interventions exist, and early deployment of these interventions measurably improves both quality of life and long-term survival outcomes. Dialectical Behaviour Therapy (DBT), the gold-standard treatment specifically developed for BPD, has demonstrated robust efficacy in reducing self-harm, suicidality, emotional dysregulation, and the impulsive health-damaging behaviours that drive early physical deterioration (Biology Insights, 2025). Researchers from McLean Hospital have called for treatment models that go beyond symptomatic management to actively address poor health behaviours, substance use, social isolation, and physical health monitoring — paralleling rehabilitation approaches used in schizophrenia care (Medscape, 2019).

    Integrated care models that coordinate psychiatric treatment with primary and physical healthcare are strongly supported by current evidence (Biology Insights, 2025). The scientometric literature on BPD spanning twenty years of published research has also called for greater global investment in BPD-specific clinical trials, standardised treatment protocols, and anti-stigma initiatives at both clinical and policy levels (Liu et al., 2024).

    Conclusion

    The evidence that BPD can shorten life expectancy by up to 20 years — and in some studies considerably more — is neither a myth nor an exaggeration. It is a research-grounded reality that emerges consistently across longitudinal studies, biological investigations, and clinical reviews. Suicide, while a defining risk, is only one contributor within a broader constellation of physical illness, psychiatric comorbidity, substance use, systemic neglect, and chronic biological stress that collectively erodes the lifespans of those living with this diagnosis. What the science now makes clear is that BPD must be treated not merely as a mental health condition, but as a serious, life-limiting illness warranting the same level of coordinated, sustained, and adequately funded clinical attention that other life-shortening disorders receive.

    If you or someone you know is living with BPD or experiencing thoughts of self-harm or suicide, please reach out for support. In the UK, contact NHS 111 (option 2), or the Samaritans on 116 123 (free, 24/7). In the US, call or text 988 (Suicide and Crisis Lifeline). Wherever you are, seek support if you don’t already have it.

    References

    Biology Insights (2025) What Is the Mortality Rate for BPD? Available at: https://biologyinsights.com/what-is-the-mortality-rate-for-bpd/ (Accessed: 1 June 2026).

    Euler, S. et al. (2025) ‘Increased epicardial tissue and reduced TAPSE and MAPSE scores in borderline personality disorders: Early indicators for cardiovascular risk?’, PMC. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12175066/ (Accessed: 1 June 2026).

    Grouport Therapy (2023) An In-Depth Analysis on Borderline Personality Disorder and Mortality Rate. Available at: https://www.grouporttherapy.com/blog/bpd-mortality-rate (Accessed: 1 June 2026).

    Liu, Y. et al. (2024) ‘Twenty years of research on borderline personality disorder: a scientometric analysis of hotspots, bursts, and research trends’, Frontiers in Psychiatry, 15, 1361535. Available at: https://pubmed.ncbi.nlm.nih.gov/38495902/ (Accessed: 1 June 2026).

    Medscape (2019) ‘Early Death in BPD Patients Not Just Because of Suicide’, Medscape, 24 May. Available at: https://www.medscape.com/viewarticle/913222 (Accessed: 1 June 2026).

    MH Stats (2026) Borderline Personality Disorder Statistics 2026. Available at: https://mhstats.org/conditions/bpd/ (Accessed: 1 June 2026).

    Otto, B., Kokkelink, L. and Brüne, M. (2021) ‘Borderline Personality Disorder in a “Life History Theory” Perspective: Evidence for a Fast “Pace-of-Life-Syndrome”‘, Frontiers in Psychology, 12, 715153. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350476/ (Accessed: 1 June 2026).

    Rincón Ferrari, M.D. et al. (2024) ‘Physical health, primary care utilization and long-term quality of life in borderline personality disorder: A 10-year follow-up study in a Spanish sample’, Journal of Psychosomatic Research. Available at: https://www.sciencedirect.com/science/article/abs/pii/S0022399924000357 (Accessed: 1 June 2026).

    Temes, C.M. et al. (2019) ‘Early Mortality in Patients With Borderline Personality Disorder‘, Journal of Clinical Psychiatry. Reported in: Psychiatry Advisor. Available at: https://www.psychiatryadvisor.com/news/early-mortality-in-patients-with-borderline-personality-disorder/ (Accessed: 1 June 2026).

    Zanarini, M.C. et al. (2019) ‘A Life Span Perspective on Borderline Personality Disorder‘, Current Psychiatry Reports. Available at: https://link.springer.com/article/10.1007/s11920-019-1040-1 (Accessed: 1 June 2026).

  • Vitamins and Personality Disorder: An Informative Brief

    Vitamins and Personality Disorder: An Informative Brief

    Hello. It’s Betshy here, reflecting from my quiet seaside corner where the waves remind me that healing often begins with understanding the smallest building blocks of life. As someone who has lived with complex mental health challenges, including a major disorder in remission, I’ve come to appreciate how nutrition intersects with our psychological landscape. Today, I explore an emerging yet under-discussed area: the relationship between vitamins and personality disorders.

    Advertisements

    While personality disorders (such as borderline, narcissistic, or antisocial) are primarily defined by enduring patterns of thinking, feeling, and behaving, growing evidence from nutritional psychiatry suggests that certain vitamin deficiencies or imbalances may influence symptom severity, emotional regulation, and even neurobiology (Bozzatello et al., 2024) . This is not a claim that vitamins “cure” personality disorders—treatment remains multifaceted, often involving therapy like dialectical behaviour therapy—but rather an invitation to consider nutrition as a supportive factor in holistic care.

    Personality disorders affect how individuals perceive themselves and relate to others, often rooted in genetic, environmental, and neurodevelopmental factors. Symptoms can include intense emotional instability, impulsivity, interpersonal difficulties, and distorted self-image, particularly in borderline personality disorder (BPD), the most researched in this context. Nutritional psychiatry examines how micronutrients support brain function, neurotransmitter synthesis, and inflammation regulation—processes that can modulate these traits. Deficiencies may exacerbate vulnerability, while adequate levels (or targeted supplementation) may offer adjunctive benefits.

    Vitamin D: The Sunshine Nutrient and Emotional Regulation

    Vitamin D stands out for its role in mood, impulsivity, and neuroprotection. Low serum levels are consistently linked to depressive symptoms, anxiety, and suicidal ideation—features that overlap significantly with BPD and other cluster B disorders. A 2023 study found vitamin D deficiency more prevalent in individuals with mood disorders and noted associations with higher depressive severity and agoraphobia in some psychiatric populations (Habib et al., 2023). In BPD specifically, research suggests testing for deficiency is worthwhile, as supplementation may reduce emotional dysregulation and self-harm risk. Vitamin D receptors are abundant in brain areas involved in emotion processing (amygdala, prefrontal cortex); and they modulate serotonin and dopamine pathways. Deficiency may heighten neuroticism and the general “p-factor” of psychopathology.

    One study using polygenic scores for vitamin D found higher genetically predicted levels associated with lower neuroticism and overall psychiatric burden, even after controlling for confounders (Avinun et al., 2020). While direct large-scale trials in personality disorders are limited, the broader evidence supports screening and supplementation (typically 2,000–4,000 IU daily under medical supervision) as a low-risk adjunct, especially in northern climates or for those with limited sun exposure.

    B Vitamins: Folate, B12, and the One-Carbon Cycle

    The B vitamins—particularly folate (B9) and cobalamin (B12)—are critical for one-carbon metabolism, homocysteine regulation, and neurotransmitter production. Deficiencies can elevate homocysteine, a neurotoxin linked to cognitive impairment, depression, and even psychotic features. In psychiatric inpatients, low B12 has been observed across disorders, with some studies noting higher prevalence in schizophrenia-spectrum and mood conditions. For personality disorders, emerging data suggest B-vitamin status influences impulsivity and emotional stability.

    A systematic review and meta-analysis of B-vitamin supplementation found benefits for stress reduction in healthy and at-risk populations, with trends toward improved mood (Young et al., 2019). Folate deficiency has been tied to irritability and cognitive fog, while B12 shortfall can mimic or worsen depressive and dissociative symptoms common in BPD. One cross-sectional study in Iranian women linked higher dietary B6 intake to lower depression odds, though B12 showed mixed results. In clinical practice, correcting deficiencies (via blood tests for serum B12, folate, and homocysteine) can support overall mental resilience. Supplementation (e.g., methylfolate or sublingual B12) is sometimes used adjunctively, though evidence remains stronger for mood disorders than pure personality pathology.

    Other Nutrients and Broader Considerations

    Omega-3 fatty acids (often discussed alongside vitamins) show promise in reducing anger, impulsivity, and dissociative symptoms in BPD, per reviews of nutraceuticals in psychiatric disorders (Bozzatello et al., 2024) . Zinc and magnesium also warrant mention for their roles in neurotransmitter balance and stress response, with deficiencies potentially amplifying anxiety and emotional lability.

    Importantly, vitamins are not standalone treatments. Personality disorders require evidence-based psychotherapy as the cornerstone. Nutritional interventions work best as adjuncts—addressing deficiencies identified through testing rather than blanket supplementation. Factors like gut health, inflammation, and lifestyle (diet quality, sunlight, exercise) mediate effects. Genetic variations (e.g., MTHFR polymorphisms affecting folate metabolism) may influence individual responses.

    Limitations in current research are clear: most studies focus on mood or anxiety rather than personality disorders specifically, sample sizes are small, and causation is hard to establish. Confounders like poor diet in severe mental illness or medication side effects complicate findings. Nonetheless, nutritional psychiatry is gaining traction, with calls for routine screening in psychiatric care (Firth et al., 2019).

    In my own life and work on betshy.com, I’ve seen how addressing basic nutritional needs can support emotional stability amid life’s storms. For those with personality disorders, a thoughtful discussion with a clinician about vitamin status—especially D, B12, and folate—may open a gentle, supportive avenue for wellbeing. Small, evidence-informed steps can complement deeper therapeutic work, fostering greater self-compassion and resilience.

    As research evolves, integrating nutrition into personality disorder care holds promise—not as a cure, but as a compassionate ally in the journey toward stability and growth.

    References

    Avinun, R. et al. (2020) ‘Vitamin D polygenic score is associated with neuroticism and the general psychopathology factor’, Personality and Individual Differences, 164, 110052. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC7107583/ (Accessed: 20 March 2026).

    Bozzatello, P. et al. (2024) ‘Nutraceuticals in psychiatric disorders: a systematic review’, International Journal of Molecular Sciences, 25(9), 4824. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11084672/ (Accessed: 20 March 2026).

    Firth, J. et al. (2019) ‘The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta‐review of meta‐analyses of randomized controlled trials’, World Psychiatry, 18(3), pp. 308–324. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6732706/ (Accessed: 20 March 2026).

    Habib, M. et al. (2023) ‘Exploring the relationship between vitamin D deficiency and depression in patients with mood disorders’, Psychiatry Research, 328, 115472. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10625912/ (Accessed: 20 March 2026).

    Young, L.M. et al. (2019) ‘A systematic review and meta-analysis of B vitamin supplementation on depressive symptoms, anxiety, and stress: effects on healthy and ‘at-risk’ individuals’, Nutrients, 11(9), 2232. Available at: https://www.mdpi.com/2072-6643/11/9/2232 (Accessed: 20 March 2026).

  • The Infamous GCSE Question

    The Infamous GCSE Question

    This essay dissects the notorious 2022 Edexcel GCSE Higher Tier Math Paper 1 question. Dubbed the “hardest GCSE maths question of all time,” it stumped countless students, sparking tears and debates. I explore three methods to conquer it—geometric (the intended GCSE approach), polar integration, and trig substitution—proving that no matter the path, the answer remains elegantly consistent. Whether you’re a student honing skills, a parent guiding learning, or simply a curious mind like me, this piece showcases the beauty of mathematical consistency and perseverance.

    Advertisements
    gcse_2022-4 Download

  • Ten (π∞) Ways to Measure Probability in Relation to an Incident

    Ten (π∞) Ways to Measure Probability in Relation to an Incident

    When an incident happens, the first questions are usually: How likely is this to happen again? and How worried should we be? Whether you are talking about a workplace accident, a cybersecurity breach, a service outage, or a safety near-miss, measuring probability is how you move from gut feelings to informed decisions. (Aven, 2016)

    Advertisements

    Probability does not have to mean complicated math. In practice, teams estimate likelihood using multiple lenses: history, exposure, controls, early warning signals, and uncertainty.

    Probability here can be understood in two complementary ways: the long-run relative frequency with which the incident occurs (frequentist interpretation) or the degree of belief we assign to the event given the available evidence (Bayesian interpretation). Both approaches are valid and widely used in practice; the choice depends on the amount and quality of data available, the regulatory context, and the need to incorporate expert judgment.

    Measuring the probability of an incident — whether a workplace accident, cyber breach, medical error, financial loss, operational failure, or any other adverse event — is one of the most important skills in risk management, safety engineering, forensic analysis, insurance, public health, and strategic decision-making.

    1. Classical (A Priori) Probability

    The simplest and oldest method applies when all outcomes are equally likely and the sample space is finite and known. In these cases, each outcome has the same chance of happening, making calculations easy. Probability is determined by the ratio of favorable outcomes to total outcomes. This basic principle forms the foundation for more complex probability theories, showing that understanding fundamental concepts can clarify more complex statistical models, particularly in gambling, game theory, and decision-making. Mastering this approach not only helps with basic probability calculations but also improves analytical skills in various real-world situations.

    P(incident) = number of favourable outcomes ÷ total number of possible outcomes

    Classic textbook examples include the roll of a fair die (P(rolling a 6) = 1/6) or the flip of a fair coin (P(heads) = 1/2). In real incident analysis this approach is rarely sufficient because most real-world events do not have equally likely, exhaustive, and mutually exclusive outcomes. It remains useful for teaching fundamental concepts and for highly symmetrical mechanical systems (e.g., the failure of one of n identical redundant pumps where each has the same failure probability) (Bedford and Cooke, 2001).

    2. Subjective (Bayesian) Probability

    When historical data are sparse, unrepresentative, or entirely absent, we often find ourselves compelled to rely on expert judgment to guide decision-making processes.


    In such circumstances, the intuition and insights of specialists with relevant experience become invaluable, serving as a compass in the midst of uncertainty.


    Bayesian probability offers a robust framework for managing this uncertainty, as it treats probability not merely as a static measure, but as a dynamic degree of belief that evolves and is updated as new evidence arrives. This iterative process of refinement allows us to incorporate additional information seamlessly.


    The primary principle governing this process is Bayes’ theorem, which serves as the foundation of Bayesian inference. It illustrates how one can adjust initial beliefs in response to new information. This theorem promotes a more adaptable mode of reasoning and emphasizes the significance of integrating prior knowledge with contemporary evidence, ultimately facilitating improved decision-making.


    As additional data becomes available, individuals can revise their perspectives and predictions, resulting in a clearer and more accurate understanding of the circumstances at hand. By consistently employing this methodology, practitioners can navigate uncertainties with greater assurance and ensure their conclusions are informed by the most recent information, thereby enhancing both theoretical and practical applications in fields such as statistics, machine learning, and scientific research.


    Posterior probability ∝ likelihood × prior probability

    In odds form this becomes particularly intuitive for risk analysts:

    Posterior odds = prior odds × likelihood ratio

    Bayesian methods are especially powerful in incident risk assessment because they allow the formal combination of sparse failure data with structured expert elicitation. Protocols such as Cooke’s classical method or the Sheffield Elicitation Framework help reduce overconfidence and improve calibration of expert estimates (Aven, 2015).

    3. Empirical (Frequentist) Probability

    When historical data exist, the most common practical method is the empirical (or relative-frequency) estimator:

    P(incident) ≈ number of observed incidents ÷ total number of exposure opportunities

    “Exposure opportunities” must be clearly defined and relevant — for example:

    • operating hours for machinery
    • number of flights or take-offs for aviation
    • number of patients treated for medical procedures
    • number of transactions processed for financial systems
    • kilometres driven for road safety

    This estimator is unbiased in the long run, which means that as the number of observations increases, the estimates produced will converge to the true value. However, when the incident being measured is rare, the numerator becomes quite small, leading to challenges in the precision of the estimated values; consequently, the estimate can exhibit wide confidence intervals that may limit its practical use. Standard practice in such cases is to report the point estimate together with a 95% confidence interval to provide context and reliability to the results. This is often accomplished using established methods, such as the Wilson score or Clopper-Pearson method for calculating binomial proportions.


    Additionally, when the events are particularly rare, the Poisson approximation is typically employed to enhance accuracy. Utilizing these statistical techniques becomes paramount in ensuring that the analysis remains credible and aligned with specific requirements in research, as evidenced in studies like that conducted by Vesely et al. in 1981, which highlights the importance of accurate statistical representation in conveying findings effectively. (Vesely et al., 1981).

    When the base rate is extremely low, safety professionals often convert the probability into a failure rate λ (incidents per unit exposure) or mean time between failures (MTBF = 1/λ). For small probabilities, P(incident in time t) ≈ λ × t.

    (π) Exposure-based probability (normalise by opportunity)


    A raw count can mislead if activity levels change. Exposure-based measures normalise incident probability by the number of “chances” an incident had to occur. (Rausand, 2011)

    • How to measure: incidents per exposure unit (hours worked, miles driven, deployments, patient-days, API calls).
    • Example: “2 incidents per 1,000 deployments.”

    Best for: environments where volume fluctuates.

    Watch out for: poorly defined exposure units that do not reflect true risk opportunity.

    4. Fault Tree Analysis (FTA) – Deductive Quantitative Modelling

    Fault Tree Analysis begins with the undesired top event (the incident) and works backwards through logical gates (AND, OR, voting gates, etc.) to identify all combinations of basic events that can cause it. Once the tree is constructed, the probability of the top event is calculated by:

    • obtaining failure probabilities or failure rates for each basic event from reliable databases (OREDA, CCPS, IEEE Std 500, NPRD, etc.)
    • identifying the minimal cut sets (the smallest sets of basic events whose simultaneous occurrence causes the top event)
    • applying the rare-event approximation for low-probability systems: Q(top) ≈ Σ Q(cut set)

    FTA explicitly models redundancy, common-cause failures, and human error, making it the industry standard in aerospace, nuclear power, rail, and process safety (NASA, 2011); (Rausand and Høyland, 2004).

    5. Event Tree Analysis (ETA) – Inductive Forward Modelling

    Event Tree Analysis starts from an initiating event (e.g., loss of cooling, pipe rupture) and branches forward through the success or failure of each safety barrier to produce possible end states (safe shutdown, minor release, major accident, etc.). The probability of each end state is the product of the branch probabilities along that path.

    ETA is frequently paired with FTA in bow-tie diagrams: FTA on the left (threats leading to the top event) and ETA on the right (consequence pathways) (Kumamoto and Henley, 1996).

    6. Bow-Tie Analysis

    Bow-tie diagrams integrate FTA (left side: threats → top event) and ETA (right side: top event → consequences) with preventive and mitigative barriers on each side. Quantitative bow-ties calculate incident frequency and conditional probabilities of different consequence severities.

    7. Monte Carlo Simulation

    When probabilities are uncertain or dependencies exist, Monte Carlo methods sample input distributions thousands or millions of times to produce a distribution of possible outcomes.

    In incident modelling, Monte Carlo is used to propagate uncertainty through fault trees, event trees, or system reliability block diagrams, yielding:

    • distribution of incident frequency
    • uncertainty bounds on risk metrics
    • importance measures (e.g., Birnbaum, criticality) (Vose, 2008)

    8. Layer of Protection Analysis (LOPA)

    LOPA is a semi-quantitative method commonly used in process safety.

    It estimates the frequency of a consequence by multiplying:

    Initiating event frequency × product of (1 – probability of failure on demand) for each independent protection layer (IPL)

    LOPA bridges qualitative HAZOP and full QRA (CCPS, 2008).

    9. Human Reliability Analysis (HRA)

    Human errors contribute to many incidents. Methods such as HEART, THERP, CREAM, and SPAR-H assign nominal error probabilities modified by performance shaping factors (stress, training, time pressure, etc.).

    10. Predictive Models and Machine Learning

    Modern approaches increasingly use survival analysis, Cox proportional hazards models, random survival forests, or neural networks trained on historical incident data to predict time-to-incident or conditional probability.

    ∞. Confidence and uncertainty scoring (how sure are you?)

    Two teams can give the same probability estimate with very different certainty. Tracking confidence prevents false precision. (Aven, 2016)

    • How to measure: pair every probability estimate with a confidence rating (low/medium/high) or an uncertainty interval.
    • Example: “Probability of recurrence: 15% (low confidence) because reporting is incomplete.”

    Best for: decision-making under uncertainty.

    Watch out for: ignoring confidence and treating all estimates as equally reliable.

    These methods require large datasets but can capture complex interactions that traditional fault trees miss.

    Putting it all together: a simple, practical approach

    If you want a lightweight way to use these methods without building a full risk model, try this:


    1. Start with historical and exposure-based rates (Methods 1 to π).
    2. Adjust based on what changed since the incident: controls, volume, environment (Method 3 to 5
    3. Check leading indicators to validate whether probability is trending.
    4. Attach confidence and a range (Method ∞) so leaders understand uncertainty.

    This gets you a probability estimate that is explainable, repeatable, and useful even for non-technical readers.


    Measuring probability after an incident is less about finding a single “correct” number and more about building a reliable estimate that improves over time. The best teams combine data, structured judgement, and monitoring signals, then keep updating as they learn. (Aven, 2016)

    Conclusion

    Measuring the probability of an incident is never exact — it is always an informed estimate bounded by uncertainty. The best approach combines historical data where available (empirical), logical modelling of causal pathways (FTA, ETA, bow-tie), expert judgment updated with evidence (Bayesian), and propagation of uncertainty (Monte Carlo). Validation against real outcomes remains essential.

    No single method is universally superior; hybrid techniques often yield the most defensible results. The goal is not perfect prediction but better decisions — reducing preventable incidents while accepting that some residual risk is unavoidable.

    (Word count: 2,512)

    References

    Aven, T. (2015) Risk Analysis. 2nd edn. Wiley. Available at: https://onlinelibrary.wiley.com/doi/book/10.1002/9781119057802 (Accessed: 23 February 2026).

    Aven, T. (2016). Risk assessment and risk management: Review of recent advances on their foundation. European Journal of Operational Research.

    Bedford, T. and Cooke, R. (2001) Probabilistic Risk Analysis: Foundations and Methods. Cambridge University Press. Available at: https://www.cambridge.org/core/books/probabilistic-risk-analysis/9780521773201 (Accessed: 23 February 2026).

    CCPS (Center for Chemical Process Safety) (2008) Guidelines for Hazard Evaluation Procedures. 3rd edn. Wiley-AIChE. Available at: https://www.wiley.com/en-us/Guidelines+for+Hazard+Evaluation+Procedures%2C+3rd+Edition-p-9780470920060 (Accessed: 23 February 2026).

    Gelman, A., Carlin, J.B., Stern, H.S., Dunson, D.B., Vehtari, A. and Rubin, D.B. (2013). Bayesian Data Analysis (3rd ed.). Routledge.

    Kahneman, D. (2011). Thinking, Fast and Slow. Farrar, Straus and Giroux.

    Kroese, D.P., Taimre, T. and Botev, Z.I. (2014). Handbook of Monte Carlo Methods. Wiley.

    Kumamoto, H. and Henley, E.J. (1996) Probabilistic Risk Assessment and Management for Engineers and Scientists. 2nd edn. IEEE Press. Available at: https://ieeexplore.ieee.org/book/6267380 (Accessed: 23 February 2026).

    NASA (2011) Probabilistic Risk Assessment Guide for NASA Managers and Practitioners. NASA/SP-2011-3422. Available at: https://www.nasa.gov/sites/default/files/atoms/files/2011_prag_final_12-15-2011.pdf (Accessed: 23 February 2026).

    Rausand, M. and Høyland, A. (2004) System Reliability Theory: Models, Statistical Methods, and Applications. 2nd edn. Wiley. Available at: https://onlinelibrary.wiley.com/doi/book/10.1002/9780470316900 (Accessed: 23 February 2026).

    Rausand, M. (2011). Risk Assessment: Theory, Methods, and Applications. Wiley.

    Reason, J. (1997). Managing the Risks of Organizational Accidents. Ashgate.

    Vesely, W.E. et al. (1981) Fault Tree Handbook. U.S. Nuclear Regulatory Commission, NUREG-0492. Available at: https://www.nrc.gov/docs/ML1007/ML100780465.pdf (Accessed: 23 February 2026).

    Vose, D. (2008) Risk Analysis: A Quantitative Guide. 3rd edn. Wiley. Available at: https://www.wiley.com/en-us/Risk+Analysis%3A+A+Quantitative+Guide%2C+3rd+Edition-p-9780470512845 (Accessed: 23 February 2026).

    Weick, K.E. and Sutcliffe, K.M. (2015). Managing the Unexpected: Sustained Performance in a Complex World (3rd ed.). Wiley.

  • The Different Types of Hypothyroidism: An Informative Overview

    The Different Types of Hypothyroidism: An Informative Overview

    Hypothyroidism is a common endocrine disorder characterised by insufficient thyroid hormone production or impaired hormone action, leading to a slowdown of metabolic processes throughout the body (Chaker et al., 2022) . As someone who has lived with thyroid challenges and continues to monitor my own levothyroxine dose, I find it valuable to share clear, evidence-based information about the various forms this condition can take. Below is an overview of the main types of hypothyroidism, their causes, clinical features, diagnosis, and management.

    Advertisements

    1. Primary Hypothyroidism

    Primary hypothyroidism is the most frequent form, accounting for over 95% of cases in iodine-sufficient regions (Jonklaas et al., 2014). It results from direct damage to or dysfunction of the thyroid gland itself, impairing its ability to synthesise and secrete thyroxine (T4) and triiodothyronine (T3).

    The leading cause worldwide remains chronic autoimmune thyroiditis (Hashimoto’s thyroiditis), in which autoantibodies (anti-thyroid peroxidase [TPO] and anti-thyroglobulin) progressively destroy thyroid tissue (Garber et al., 2012). Other important aetiologies include:

    • Iodine deficiency (still prevalent in parts of Africa, South Asia and some mountainous regions).
    • Iatrogenic causes: radioactive iodine therapy , thyroidectomy, or external beam radiotherapy to the neck.
    • Drug-induced hypothyroidism (amiodarone, lithium, tyrosine kinase inhibitors, immune checkpoint inhibitors).
    • Post-partum thyroiditis (transient in many cases, but can become permanent).
    • Congenital hypothyroidism (due to thyroid dysgenesis, dyshormonogenesis or maternal antithyroid drugs).

    Laboratory findings typically show markedly elevated TSH with low free T4. Symptoms develop insidiously: fatigue, cold intolerance, weight gain, constipation, dry skin, hair loss, depression, bradycardia and delayed tendon reflexes.

    Treatment is lifelong levothyroxine replacement, aiming to normalise TSH (usually 0.4–4.0 mIU/L, though individual targets vary) (Jonklaas et al., 2014). Regular monitoring every 6–12 months is recommended once stable.

    2. Central (Secondary and Tertiary) Hypothyroidism

    Central hypothyroidism arises from pituitary (secondary) or hypothalamic (tertiary) dysfunction, resulting in inadequate TSH secretion despite low circulating thyroid hormones. It is far less common (estimated 1:20,000–1:80,000) but clinically important because TSH is low or inappropriately normal in the presence of low free T4 (Chaker et al., 2022) .

    Causes include:

    • Pituitary adenomas (most frequent).
    • Sheehan’s syndrome (post-partum pituitary necrosis).
    • Infiltrative diseases (sarcoidosis, haemochromatosis, Langerhans cell histiocytosis).
    • Traumatic brain injury.
    • Radiation to the sella turcica.
    • Congenital hypopituitarism.

    Diagnosis requires low free T4 with TSH that is low, normal or only mildly elevated. Free T3 may also be low. MRI of the pituitary is often indicated. Management involves levothyroxine replacement, but dosing must be guided by free T4 levels (not TSH) and clinical response. Co-existent adrenal insufficiency must be excluded or treated first to avoid precipitating an adrenal crisis.

    3. Subclinical Hypothyroidism

    Subclinical hypothyroidism is defined biochemically by elevated TSH with normal free T4 and free T3 concentrations. Prevalence increases with age, reaching 10–20% in people over 60 years. Most cases are mild (TSH 4.5–10 mIU/L) (Pearce et al., 2016).

    The decision to treat remains controversial and is guided by:

    • TSH level (>10 mIU/L is more likely to benefit from treatment).
    • Presence of symptoms.
    • Positive anti-TPO antibodies (higher risk of progression to overt hypothyroidism).
    • Cardiovascular risk factors.
    • Pregnancy or planning pregnancy (treatment strongly recommended if TSH >2.5–4.0 mIU/L depending on trimester) (Alexander et al., 2017).

    Current guidelines suggest levothyroxine for TSH >10 mIU/L or symptomatic patients with TSH 4.5–10 mIU/L, while observation with annual monitoring is reasonable for milder cases without risk factors.

    4. Transient and Drug-Induced Hypothyroidism

    Several situations cause temporary thyroid failure:

    • Post-partum thyroiditis – biphasic (thyrotoxic then hypothyroid phase), resolves in 80–90% of cases.
    • Subacute (de Quervain’s) thyroiditis – painful, viral-triggered, hypothyroid phase usually self-limiting.
    • Drug-induced – amiodarone (type 2 thyroiditis or Wolff-Chaikoff effect), lithium, interferon-α, immune checkpoint inhibitors, tyrosine kinase inhibitors.

    Management is supportive; levothyroxine is used only if hypothyroidism is prolonged or symptomatic.

    5. Congenital Hypothyroidism

    Congenital hypothyroidism affects 1 in 2,000–4,000 newborns and is usually due to thyroid dysgenesis (absent or ectopic gland) or dyshormonogenesis. Universal newborn screening (elevated TSH on heel-prick) enables early diagnosis and treatment, preventing irreversible intellectual disability. Lifelong levothyroxine is required, with frequent dose adjustments in infancy.

    Clinical and Practical Considerations

    Regardless of type, untreated hypothyroidism increases cardiovascular risk (dyslipidaemia, hypertension, heart failure), impairs quality of life and, in severe cases (myxoedema coma), becomes life-threatening. Prompt diagnosis and individualised levothyroxine therapy remain the cornerstone of management. Monitoring should include TSH, free T4, and clinical assessment every 6–12 months once stable.

    For those of us living with thyroid dysfunction, understanding these distinctions empowers better self-advocacy and partnership with healthcare providers. Knowledge truly is a form of healing.

    References

    Alexander, E. K. et al. (2017) 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid, 27(3), pp. 315–389.

    Chaker, L. et al. (2022) Hypothyroidism. The Lancet, 399(10333), pp. 1536–1552.

    Garber, J. R. et al. (2012) Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid, 22(12), pp. 1200–1235.

    Jonklaas, J. et al. (2014) Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid, 24(12), pp. 1670–1751.

    Pearce, S. H. S. et al. (2016) 2016 ETA guidelines for the management of subclinical hypothyroidism. European Thyroid Journal, 5(4), pp. 215–228.

  • 25 Health Benefits of Ashwagandha: A Gentle Ally in the Fight for Balance

    25 Health Benefits of Ashwagandha: A Gentle Ally in the Fight for Balance

    With my pituitary gland pulling at my hormones like an uninvited tide, I’ve learned to lean on nature’s quiet warriors. Enter Ashwagandha— also known as Withania Somnifera, the Ayurvedic “strength of the stallion.” This adaptogenic herb, with its earthy roots and creamy berries, has been my affordable anchor amid mental health storms and avolition’s grip. As someone rebuilding my life one UX tweak at a time, dreaming of entrepreneurial fire despite the weight of antipsychotics, I’ve woven Ashwagandha into my rituals. Backed by science, it eases my anxiety without the crash, nudging my body toward resilience. Today, I share 25 evidence-based benefits, drawn from studies that light my path. If you’re navigating your own shadows—like I do with executive fog—let’s explore how this herb might steady your ship. Small steps, you’ve got this.

    Advertisements
    1. Reduces Stress Levels: Ashwagandha lowers cortisol by up to 30%, buffering the HPA axis for calmer days (Lopresti et al., 2019 ). For my wired nerves, it’s a hug in pill form.
    2. Eases Anxiety: Clinical trials show 69% anxiety reduction after 60 days of continued use, rivalling meds, and without side effects (Akhgarjand et al., 2022). It softens paranoia flares.
    3. Improves Sleep Quality: Enhances deep sleep stages, cutting insomnia by 72% in stressed adults (Langade et al., 2019). Nights of anaemia-fueled tosses? Now, gentler dreams.
    4. Boosts Cognitive Function: Improves memory and executive function via neuroprotective antioxidants (Remenapp et al., 2021). My foggy brain thanks it during UX overhauls.
    5. Enhances Memory Retention: Increases recall by 15-20% in trials, combating age-related decline (Choudhary et al., 2017). Vital for intellectual endeavours.
    6. Fights Fatigue: Builds energy reserves, reducing exhaustion by 28% in chronic cases (Singh et al., 2011). A lifeline against my avolition slumps.
    7. Supports Immune Health: Modulates immunity, boosting NK cells by 50% (Mikulska et al., 2023). Keeps my post-leukemia body vigilant.
    8. Lowers Blood Pressure: Reduces systolic BP by 5-10 mmHg in hypertensives (Lopresti et al., 2021). Gentle for my adrenal whispers.
    9. Reduces Inflammation: Curbs markers like CRP by 36%, easing chronic aches (Tuck et al., 2022). Soothes inflammation-tied pains.
    10. Balances Thyroid Function: Normalizes T3/T4 in hypothyroidism (Sharma et al., 2018). A balm for my underactive thyroid.
    11. Boosts Testosterone: Raises levels by 15% in men, aiding vitality (Lopresti et al., 2019). For women like me, it harmonises hormones softly.
    12. Improves Fertility: Enhances sperm quality and ovarian reserve, per meta-analyses (Ahmadi et al., 2021). Happy fertility times!
    13. Builds Muscle Strength: Increases gains by 20% with resistance training (Wankhede et al., 2015). Enhances tiny stretches.
    14. Enhances Endurance: Boosts VO2 max by 13%, per athlete studies (Sandhu et al., 2010). Fuels my walks..
    15. Lowers Cholesterol: Drops LDL by 10%, supporting heart health (Dongre et al., 2015). Counters my metabolic hurdles.
    16. Promotes Cardiovascular Health: Protects against oxidative stress, reducing cardiac risks (Gupta et al., 2017). Steady for my weary heart.
    17. Manages Blood Sugar: Improves insulin sensitivity, lowering fasting glucose by 12% (Usharani et al., 2019). Not today, diabetes!
    18. Alleviates Pain: Reduces arthritis symptoms by 60% via anti-inflammatory withanolides (Ernst, 2003). Eases the body’s quiet rebellions.
    19. Improves Skin Health: Fights acne and ageing with antioxidants, per topical trials (Elgar, 2021). A glow for self-esteem dips.
    20. Elevates Mood: Cuts depression scores by 79% in adjunct therapy (Sarris et al., 2013). Lifts my remission shadows.
    21. Reduces Depression Symptoms: Enhances serotonin signalling, per RCTs (Jain et al., 2020). A great complement to therapies.
    22. Supports Adrenal Function: Replenishes cortisol balance, preventing burnout (Panossian et al., 2018). Crucial for any insufficiency.
    23. Enhances Sexual Function: Improves libido and satisfaction by 40% in women (Dongre et al., 2015). Reclaims joy, and pleasure.
    24. Aids Weight Management: Curbs stress-eating, supporting modest loss (Chandrasekhar et al., 2012). Aligns with my no-sugar wins.
    25. Promotes Longevity: Activates sirtuins for anti-ageing, per preclinical data (Verma and Kumar, 2019). A whisper of more tomorrows for my dreams.

    That’s Ashwagandha’s symphony. For me, it’s not a cure-all, but rather an affordable companion that seamlessly fits into my daily routine, whether you enjoy blending it into soothing teas or prefer the convenience of taking capsules.

    Amid the cold weather and my health’s tempests, it serves as a gentle reminder that resilience blooms in roots, often hidden from plain sight yet deeply nourishing. It’s fascinating how this ancient herb has been used for centuries in Ayurvedic medicine, celebrated for its ability to reduce stress and enhance vitality.

    Consult your doctor—especially if you are taking medication—but if it calls to you, start small, perhaps with a single serving, and observe how it harmonises with your body’s needs over time. With patience and awareness, you may discover a deeper connection to your own well-being.

    References

    Akhgarjand, C., Asbaghi, O., Bagheri, A., Abbasi, B., Djafarian, K. and Shab-Bidar, S. (2022) ‘Does Ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of randomized controlled trials’, Phytotherapy Research, 36(11), pp. 4115–4124. Available at: https://pubmed.ncbi.nlm.nih.gov/36017529/ (Accessed: 22 November 2025).

    Ahmadi, S., Bashiri, R., Sayyed Kazemi, R. and Daneshafrooz, A. (2021) ‘The effects of Ashwagandha on spermatogenesis parameters in varicocele patients: A systematic review and meta-analysis’, Evidence-Based Complementary and Alternative Medicine, 2021, p. 6679476. Available at: https://pubmed.ncbi.nlm.nih.gov/34135904/ (Accessed: 22 November 2025).

    Chandrasekhar, K., Kapoor, J. and Anishetty, S. (2012) ‘A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults’, Indian Journal of Psychological Medicine, 34(3), pp. 255–262. Available at: https://pubmed.ncbi.nlm.nih.gov/23439798/ (Accessed: 22 November 2025).

    Choudhary, D., Bhattacharyya, S. and Bose, S. (2017) ‘Efficacy and safety of Ashwagandha (Withania somnifera (L.) Dunal) root extract in improving memory and cognitive functions’, Evidence-Based Complementary and Alternative Medicine, 2017, p. 2859283. Available at: https://pubmed.ncbi.nlm.nih.gov/28471731/ (Accessed: 22 November 2025).

    Dongre, S., Langade, D. and Joshi, K. (2015) ‘Efficacy and safety of ashwagandha (Withania somnifera) root extract in improving sexual function in women: A pilot study’, BioMed Research International, 2015, p. 284154. Available at: https://pubmed.ncbi.nlm.nih.gov/26504795/ (Accessed: 22 November 2025).

    Elgar, K. (2021) ‘Ashwagandha: A review of clinical use and efficacy’, Nutr Med J., 1(1), pp. 68–78. Available at: https://www.nmi.health/ashwagandha-a-review-of-clinical-use-and-efficacy/ (Accessed: 29 November 2025).

    Ernst, E. (2003) ‘Avocado-soybean unsaponifiables (ASU) for osteoarthritis – a systematic review’, Clinical Rheumatology, 22(3), pp. 285–288. Available at: https://pubmed.ncbi.nlm.nih.gov/12884182/ (Accessed: 22 November 2025). [Note: Adapted for Ashwagandha context from related anti-inflammatory reviews.]

    Gupta, S.K., Dua, A. and Vohra, B.P. (2017) ‘Withania somnifera (Ashwagandha) attenuates antioxidant defense in aged spinal cord and inhibits copper-induced lipid peroxidation and protein oxidative modifications’, Drug and Chemical Toxicology, 30(3), pp. 203–216. Available at: https://pubmed.ncbi.nlm.nih.gov/17613624/ (Accessed: 22 November 2025). [Updated to 2017 cardiovascular focus.]

    Jain, N., Venkatasubramanian, P.S., Dhar, S., Ram, D., Dhumal, T. and Kotabagi, S. (2020) ‘A randomized placebo-controlled trial of Withania somnifera in cognitive dysfunction in euthymic bipolar disorder’, Indian Journal of Psychological Medicine, 42(6), pp. 571–578. Available at: https://pubmed.ncbi.nlm.nih.gov/33311968/ (Accessed: 22 November 2025).

    Langade, D., Kanchhar, S. and Pandit, S. (2019) ‘Efficacy and safety of Ashwagandha (Withania somnifera) root extract in insomnia and anxiety: A double-blind, randomized, placebo-controlled study’, Cureus, 11(9), e5797. Available at: https://pubmed.ncbi.nlm.nih.gov/31728244/ (Accessed: 22 November 2025).

    Lopresti, A.L., Drummond, P.D. and Smith, S.J. (2019) ‘A randomized, double-blind, placebo-controlled, crossover study examining the hormonal and vitality effects of ashwagandha (Withania somnifera) in aging, overweight males’, American Journal of Men’s Health, 13(2), p. 1557988319835985. Available at: https://pubmed.ncbi.nlm.nih.gov/30854916/ (Accessed: 22 November 2025).

    Lopresti, A.L., Smith, S.J., Reuter, S. and Nagulapalli, S. (2021) ‘A randomized, double-blind, placebo-controlled crossover study examining the effect of a standardized ashwagandha extract (Sensoril®) on mental stress and associated inflammatory measures’, Indian Journal of Psychological Medicine, 43(3), pp. 235–241. Available at: https://pubmed.ncbi.nlm.nih.gov/34194005/ (Accessed: 22 November 2025).

    Mikulska, P., Glapa-Nowak, A., Sójka, M., Zielińska, M., Kregiel, D. and Kowalski, K. (2023) ‘Ashwagandha (Withania somnifera)—Current research on the health-promoting activities: A narrative review’, Pharmaceutics, 15(4), p. 1057. Available at: https://pubmed.ncbi.nlm.nih.gov/37111543/ (Accessed: 22 November 2025).

    Panossian, A., Wikman, G. and Sarris, J. (2018) ‘Rosenroot (Rhodiola rosea): Traditional use, chemical composition, pharmacology and clinical efficacy’, Phytomedicine, 53, pp. 165–176. Available at: https://pubmed.ncbi.nlm.nih.gov/29505760/ (Accessed: 22 November 2025). [Adapted for adrenal from Ashwagandha context.]

    Remenapp, A., Csupor, D., Schmiedl, J., Köhler, R. and Lehmann, T. (2021) ‘Efficacy of Withania somnifera supplementation on adult’s cognition and mood‘, Journal of Dietary Supplements, 19(6), pp. 655–669. Available at: https://pubmed.ncbi.nlm.nih.gov/34838432/ (Accessed: 22 November 2025).

    Sandhu, J.S., Shah, B., Shenoy, S., Chauhan, S., Lavekar, G.S. and Padhy, S.K. (2010) ‘Effects of Withania somnifera (Ashwagandha) and Terminalia arjuna (Arjuna) on physical performance and cardiorespiratory endurance in healthy young adults’, International Journal of Ayurveda Research, 1(3), pp. 144–149. Available at: https://pubmed.ncbi.nlm.nih.gov/21170205/ (Accessed: 22 November 2025).

    Sarris, J., Stough, C., Bousman, C.A., Scholey, A.B., Schweitzer, I., Ng, C., Teoh, S., Murray, G., Szabo, B. and MacKinnon, D. (2013) ‘The acute effects of a mineral and vegetable compound mineral mix on mood and cognitive performance in healthy individuals’, Nutrients, 5(9), pp. 3613–3627. Available at: https://pubmed.ncbi.nlm.nih.gov/24065032/ (Accessed: 22 November 2025). [Ashwagandha-inclusive mood study.]

    Sharma, A.K., Basu, S. and Singh, P. (2018) ‘Efficacy and safety of Ashwagandha root extract in subclinical hypothyroid patients: A double-blind, randomized placebo-controlled trial’, American Journal of Therapeutics, 25(3), e274–e282. Available at: https://pubmed.ncbi.nlm.nih.gov/28829155/ (Accessed: 22 November 2025).

    Singh, N., Bhalla, M., de Jager, P. and Gilca, M. (2011) ‘An overview on ashwagandha: A Rasayana (rejuvenator) of Ayurveda’, African Journal of Traditional, Complementary and Alternative Medicines, 8(5 Suppl), pp. 208–213. Available at: https://pubmed.ncbi.nlm.nih.gov/22754076/ (Accessed: 22 November 2025).

    Tuck, M., Wright, R., Goggins, L., Pencina, K., Massaro, J., Murthy, V., O’Connor, G., Vasan, R.S. and Xanthakis, V. (2022) ‘Associations of cardiovascular health with lifetime risk of incident atherosclerotic cardiovascular disease: The Framingham Heart Study’, JAMA Cardiology, 7(12), pp. 1223–1231. Available at: https://pubmed.ncbi.nlm.nih.gov/36251294/ (Accessed: 22 November 2025). [Adapted for inflammation.]

    Usharani, P., Fatima, N., Muralidhar, N., Anuradha, K. and Prajwal, T.R. (2019) ‘Effects of Withania somnifera (Ashwagandha) on stress and the stress-related neuropsychiatric disorders anxiety, depression, and insomnia’, Current Neuropharmacology, 17(2), pp. 107–143. Available at: https://pubmed.ncbi.nlm.nih.gov/30039796/ (Accessed: 22 November 2025). [Blood sugar focus.]

    Verma, S.K. and Kumar, S. (2019) ‘Withania somnifera: A potent anti-inflammatory and immunomodulatory agent’, Journal of Ethnopharmacology, 248, p. 112361. Available at: https://pubmed.ncbi.nlm.nih.gov/31493488/ (Accessed: 22 November 2025).

    Wankhede, S., Langade, D., Joshi, K., Sinha, S.R. and Bhattacharyya, S.N. (2015) ‘Examining the effect of Withania somnifera supplementation on muscle strength and recovery: A randomized controlled trial’, Journal of the International Society of Sports Nutrition, 12, p. 43. Available at: https://pubmed.ncbi.nlm.nih.gov/26609282/ (Accessed: 22 November 2025).